BC-3 (ATCC® CRL-2277)

Organism: Homo sapiens, human  /  Cell Type: B lymphocyte  /  Tissue: Pleura, pleural effusion  /  Disease: lymphoma

Organism Homo sapiens, human
Tissue Pleura, pleural effusion
Cell Type B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 2  [Cells contain Kaposi's sarcoma-associated herpesvirus genome]
Disease lymphoma
Age 85 years
Gender male
Ethnicity Caucasian
Applications This cell line is a suitable transfection host.
It is ideal for the isolation and study of KSHV.
Derivation
The cells were established from pleural effusion from a human immunodeficiency virus (HIV) negative patient diagnosed with primary effusion (body cavity based) lymphoma (PEL).
BC-3 is a primary effusion lymphoma cell line originated in 1995 by Leandros Arvanitakis and Ethel Cesarman.
Clinical Data
85 years
Caucasian
male

Antigen Expression
CD30 +; CD38 +; CD45 +; CD 54 +; CD71 +; HLA-DR +; EMA + (epithelial membrane antigen); CD2 -; CD3 -; CD4 -; CD5 -, CD8 -; CD19 -; CD20 -; CD21 -; CD22 -
Comments

The BC-3 cell line contains the viral genome for Kaposi's sarcoma-associated herpesvirus (KSHV, provisionally designated HHV-8).

KSHV is a recently identified and partially uncharacterized virus.

BC-3 cells are negative for both HIV and Epstein-Barr virus (EBV).

They are also reported to be negative for herpes simplex virus 1 & 2 (HSV-1 and HSV-2) and cytomegalovirus (CMV).

The BC-3 cell line allows in vitro culture of KSHV viral genomes in the absence of EBV.

BC-3 has an intact KSHV genome of about 170 kb both in the cell line and in the viral isolate.

The cells do not express B-cell lineage restricted antigens or kappa or lambda immunoglobulin light chains or T-cell lineage-restricted antigens.

The cells do express activation antigens.

Complete Growth Medium RPMI 1640 medium, 80%; fetal bovine serum, 20%
Subculturing

Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 5 x 105 viable cells/mL. Maintain cell density between 5 x 105 and 2 x 106 viable cells/mL.


Medium Renewal: 2 to 3 times a week.  
Cryopreservation
Culture medium, 95%; DMSO, 5%
Culture Conditions
Temperature: 37°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
STR Profile
Amelogenin: X
CSF1PO: 11,12
D13S317: 11
D16S539: 12
D5S818: 11,12
D7S820: 10,12
THO1: 6,9
TPOX: 8,11
vWA: 14,18
Name of Depositor Cornell Res. Fndn., Inc.
Year of Origin 1995
References

Arvanitakis L, et al. Establishment and characterization of a primary effusion (body cavity- based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood 88: 2648-2654, 1996. PubMed: 8839859

Cesarman E, et al. KSHV positive cell lines. US Patent 5,908,773 dated Jun 1 1999

Basic Documentation
References

Arvanitakis L, et al. Establishment and characterization of a primary effusion (body cavity- based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood 88: 2648-2654, 1996. PubMed: 8839859

Cesarman E, et al. KSHV positive cell lines. US Patent 5,908,773 dated Jun 1 1999